What is the 13F Pro Quality Score for HCWB?

13F Pro ranks HCW Biologics Inc. (HCWB) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View HCWB's current score at https://13fpro.ai/company/HCWB (free sign-up required for the full ranking).

Which hedge funds own the most HCWB stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of HCWB include JANE STREET GROUP,, CITADEL ADVISORS, HRT FINANCIAL. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/HCWB as soon as new 13F filings post.

Where does 13F Pro source HCWB data?

All HCW Biologics Inc. fundamentals and ownership data come directly from SEC EDGAR. HCW Biologics Inc. files with the SEC under CIK 1828673. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is HCWB in?

HCW Biologics Inc. (HCWB) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is HCWB research updated on 13F Pro?

HCWB's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

HCW Biologics Inc.(HCWB)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1828673 HCWB stock profile & AI dashboard →

13F Pro Quality Score

30.3/100

Rank #2,493 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why HCWB Scores 30/100

exact factor attribution · 2026-09-11

HCWB's composite is driven by revenue growth and earnings growth, held back by scale and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+8.2 pts

91th pct

Earnings growth

+2.1 pts

91th pct

Institutional flow

-1.6 pts

19th pct

Shareholder dilution

-2.4 pts

2th pct

Capital efficiency

-3.3 pts

18th pct

Earnings quality

-4.9 pts

1th pct

Profitability

-5.3 pts

15th pct

Free cash flow

-6.0 pts

10th pct

Scale

-6.5 pts

6th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

HCWB Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for HCW Biologics Inc. (HCWB), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores HCWB at 30.3/100 on a 32-signal composite quality model, placing it at rank #2,493 of 2,962 stocks — the bottom half of the AI-ranked universe. Top institutional holders of HCWB by reported 13-F value include JANE STREET GROUP, CITADEL ADVISORS, HRT FINANCIAL, based on the most recent SEC filings. HCWB trades on the Nasdaq exchange and files with the SEC under CIK 1828673. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate HCWB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for HCW Biologics Inc. directly from SEC EDGAR. HCW Biologics Inc.'s 13F Pro composite quality score has ranged between 4 and 30 since 2026, currently 30.3 — an improving long-term trajectory across 8 quarterly and live scoring snapshots.

✦

Fun facts about HCW Biologics Inc.

Quirks, history, and lore behind HCWB — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · small-cap · listed on Nasdaq · headquartered in South Florida.
2
The Numbers
Annual revenue in the low single-digit millions — a clinical-stage company still burning cash as it bets on a novel immunology platform.
3
The History
Founded in the early 2000s by scientists with deep roots in cytokine biology, it went public on Nasdaq in 2021 to fund its pipeline.
4
The Secret
Its core technology targets inflammaging — the chronic low-grade inflammation tied to aging — aiming to reset the immune system rather than just suppress it.
5
The Lore
The company's platform is built around engineered fusion proteins that selectively expand regulatory T cells, a niche so specific it barely registers outside immunology conferences.
6
The Giveaway
Its ticker is four letters starting with HCWB, its name literally spells out its founders' initials, and its lead programs target aging-related immune dysfunction — HCW Biologics.

▶ Think you know your stocks? Play the Daily Ticker

Net Income

Q2 2026

$-5.2M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-97.9% YoY

$54.2KFY 2025

FY22 $6.7MFY23 $2.8MFY24 $2.6MFY25 $54.2K

Net Income

+73.5% YoY

$-8.0MFY 2025

FY22 $-14.9MFY23 $-25.0MFY24 $-30.0MFY25 $-8.0M

Operating Income

+55.3% YoY

$-13.2MFY 2025

FY22 $-15.1MFY23 $-25.7MFY24 $-29.5MFY25 $-13.2M

EPS (Diluted)

+65.7% YoY

$-10.63FY 2025

FY22 $-0.42FY23 $-0.70FY24 $-30.96FY25 $-10.63

Total Assets

-18.9% YoY

$24.5MFY 2025

FY22 $46.8MFY23 $28.5MFY24 $30.2MFY25 $24.5M

Total Debt

-50.3% YoY

$6.8MFY 2025

FY22 $44.7MFY23 $6.4MFY24 $13.7MFY25 $6.8M

Op. Cash Flow

+5.9% YoY

$-13.4MFY 2025

FY22 $-10.4MFY23 $-22.5MFY24 $-14.2MFY25 $-13.4M

Free Cash Flow

+7.6% YoY

$-13.4MFY 2025

FY22 $-20.7MFY23 $-28.7MFY24 $-14.5MFY25 $-13.4M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$54.2K -97.9%	$2.6M -9.7%	$2.8M -57.7%	$6.7M	$0.00 -100.0%	$4.1M
Net Income	$-8.0M +73.5%	$-30.0M -20.1%	$-25.0M -67.7%	$-14.9M -15.8%	$-12.9M -121.7%	$-5.8M
Operating Income	$-13.2M +55.3%	$-29.5M -14.5%	$-25.7M -70.6%	$-15.1M -12.8%	$-13.4M -129.5%	$-5.8M
EPS (Diluted)	$-10.63 +65.7%	$-30.96 -4322.9%	$-0.70 -66.7%	$-0.42 +39.1%	$-0.69	—
Total Assets	$24.5M -18.9%	$30.2M +6.0%	$28.5M -39.1%	$46.8M -12.5%	$53.5M +247.5%	$15.4M
Total Debt	$6.8M -50.3%	$13.7M +113.2%	$6.4M -85.6%	$44.7M	$0.00	—
Operating Cash Flow	$-13.4M +5.9%	$-14.2M +36.8%	$-22.5M -116.8%	$-10.4M +5.4%	$-11.0M -5.2%	$-10.4M
Free Cash Flow	$-13.4M +7.6%	$-14.5M +49.5%	$-28.7M -39.0%	$-20.7M -87.4%	$-11.0M -3.8%	$-10.6M

Get alerted when HCWB's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for HCW Biologics Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of HCWB

JANE STREET GROUP, LLC
$260.2K52,138 sh
CITADEL ADVISORS LLC
$99.5K19,942 sh
HRT FINANCIAL LP
$67.0K13,583 sh
VANGUARD FIDUCIARY TRUST CO
$32.5K6,510 sh
Tower Research Capital LLC (TRC)
$20.5K4,117 sh
Connective Capital Management, LLC
$16.7K3,338 sh
VANGUARD CAPITAL MANAGEMENT LLC
$10.0K2,003 sh
Golden State Wealth Management, LLC
$8.3K1,667 sh
BARCLAYS PLC
$953.00191 sh
OSAIC HOLDINGS, INC.
$20.004 sh

Fund	Value	Shares
JANE STREET GROUP, LLC	$260.2K	52,138
CITADEL ADVISORS LLC	$99.5K	19,942
HRT FINANCIAL LP	$67.0K	13,583
VANGUARD FIDUCIARY TRUST CO	$32.5K	6,510
Tower Research Capital LLC (TRC)	$20.5K	4,117
Connective Capital Management, LLC	$16.7K	3,338
VANGUARD CAPITAL MANAGEMENT LLC	$10.0K	2,003
Golden State Wealth Management, LLC	$8.3K	1,667
BARCLAYS PLC	$953.00	191
OSAIC HOLDINGS, INC.	$20.00	4

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put HCWB on your watchlist

Track score changes the day HCW Biologics Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is HCWB a good stock to buy?

13F Pro's AI-powered analysis of HCW Biologics Inc. (HCWB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for HCWB are available on the HCWB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. HCWB is classified as a small company.

Which hedge funds own HCWB?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling HCWB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of HCW Biologics Inc.'s investment landscape.